Global mRNA Cancer Vaccines and Therapeutics Market Growth (Status and Outlook) 2023-2029

Global mRNA Cancer Vaccines and Therapeutics Market Growth (Status and Outlook) 2023-2029

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

LPI (LP Information)' newest research report, the “mRNA Cancer Vaccines and Therapeutics Industry Forecast” looks at past sales and reviews total world mRNA Cancer Vaccines and Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected mRNA Cancer Vaccines and Therapeutics sales for 2023 through 2029. With mRNA Cancer Vaccines and Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Cancer Vaccines and Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global mRNA Cancer Vaccines and Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Cancer Vaccines and Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global mRNA Cancer Vaccines and Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Cancer Vaccines and Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Cancer Vaccines and Therapeutics.

The global mRNA Cancer Vaccines and Therapeutics market size is projected to grow from US$ 137.3 million in 2022 to US$ 483.9 million in 2029; it is expected to grow at a CAGR of 19.7% from 2023 to 2029.

North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.

The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.

This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Cancer Vaccines and Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas

Segmentation by application
Infectious Disease
Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology

Please note: The report will take approximately 2 business days to prepare and deliver.